Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
107
-
Total 13F shares, excl. options
-
66.2M
-
Shares change
-
+3.52M
-
Total reported value, excl. options
-
$152M
-
Value change
-
+$7.4M
-
Put/Call ratio
-
0.69
-
Number of buys
-
48
-
Number of sells
-
-51
-
Price
-
$2.30
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q2 2023
142 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q2 2023.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 107 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 66.2M shares
of 193M outstanding shares and own 34.22% of the company stock.
Largest 10 shareholders include BlackRock Inc. (9.97M shares), Two Seas Capital LP (8.28M shares), Whitefort Capital Management, LP (8.09M shares), VANGUARD GROUP INC (5.82M shares), MORGAN STANLEY (5.08M shares), Rubric Capital Management LP (3.4M shares), Hudson Bay Capital Management LP (2.85M shares), GEODE CAPITAL MANAGEMENT, LLC (2.6M shares), Woodline Partners LP (2.47M shares), and CITADEL ADVISORS LLC (2.3M shares).
This table shows the top 107 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.